Introduction
============

Non-compliance is a frequent phenomenon in outpatient care. It is estimated that, in general, at least 50% of patients fail to receive full treatment benefit due to inadequate compliance ([@b31]). This, in turn, leads to profound consequences. Non-compliance is a cause of additional procedures or treatment, and it contributes to unnecessary hospital admissions: up to 10% hospitalizations are attributed to this misbehavior ([@b34]; [@b23]; [@b17]). With its enormous cost burden, non-compliance is not only a serious medical problem, but also a social problem.

Low compliance is a well-known phenomenon in asymptomatic diseases of which hypertension is the most frequently studied one. In contrast to this condition, ischemic heart disease is a classical example of symptomatic disease. Thus, one may assume that chest pain episodes should motivate patients to follow doctors' instructions. Nevertheless, even anti-anginal treatment with symptom-releasing drugs such as nitrates is not fully executed by patients ([@b21]).

Beta-blockers are the drugs of choice in the therapy for chronic stable angina. In their case, non-compliance seems to be present as well, despite possible consequences. A recent study based on self-reports found as many as 56% of coronary artery disease patients non-compliant with this class of drugs ([@b26]). However, unlike the other antianginal treatment, which with non-compliance became just ineffective, the consequences of non-compliance with beta-blockers are much more profound and include increased risk of incident coronary heart disease and death ([@b18]; [@b27]). Thus, the problem of patient compliance during beta-blocker treatment is of highest clinical importance.

A number of factors such as intelligence, memory, age, education, and a number of drugs a patient takes does not seem to influence the level of adherence ([@b8]). On the contrary, existing experience points to the number of daily doses as an important predictor of patient compliance ([@b7]), although the benefit of once-daily over twice-daily dosing is still not fully proved in a number of clinical conditions. Two decades ago, this concept was tested in the field of beta-blockers, revealing better compliance with once-daily formulation ([@b3]). However, the methodology of that study, ie, the assessment of compliance by means of simple pill count, did not allow any insight in dose timing history and until now little is known about patient compliance with beta-blockers. Recently, new possibilities have come with the use of electronic monitoring, which is the most precise method of compliance assessment. This methodology has been shown to be more accurate in revealing non-compliance than refill data, pill count, provider assessment, or patient self-reporting ([@b35]). Therefore, the BETTER trial (once-daily betaxolol vs twice-daily metoprolol: the effect on patient compliance and clinical outcome) aimed to precisely assess the impact of different dosing regimens of beta-blockers on compliance and clinical outcome to find out whether once-daily beta-blocker regimen ensures real clinical advantage.

Materials and methods
=====================

Patients and study design
-------------------------

This was an open, randomized, single-center, parallel-group study, investigating compliance in patients treated with betaxolol or metoprolol. The study protocol has been *a priori* approved by the Ethical Committee of the Medical University of Lodz.

The inclusion criteria were ischemic heart disease outpatients CCS class I-II, aged 40--75 years, beta-blockers-naive, whose mental state enabled conscious participation in the study and who had signed a conscious consent form.

The main exclusion criteria were unstable angina pectoris, NYHA class III and IV heart failure, heart rate \<60/min, II° or III° atrio-ventricular block, systolic blood pressure below 90 mmHg, symptomatic infection, and any conditions requiring help of others with drug administration (eg, impaired dexterity, serious visual defect).

The sample size of 48 patients in each group was obtained by assuming overall compliance (primary outcome measure) difference between the group of 10%, and common standard deviation of 15%, with a power of 90% and α = 0.05 ([@b30]). Therefore, the study was designed to cover 100 patients.

At the first visit, the eligibility criteria were assessed and written informed consent was obtained. All patients were provided with self-control diaries, in which they were asked to record the number of chest pain episodes per week and the number of short-acting nitrate doses taken in case of need (eg, nitroglycerine in tablets or aerosol, izosorbide dinitrate in aerosol) as well as any relevant information concerning health and medication.

After the next 2 weeks of observation, patients were randomized to the two groups: the once-daily (od) group was informed to take 20 mg betaxolol (Lokren®, Sanofi-Synthelabo, France) at 07:00; and the twice-daily (bd) group was informed to take 100 mg metoprolol tartrate (metoprolol, ICN Polfa Rzeszow, Poland) in two 50 mg doses, to be taken at 07:00 and 19:00.

The active treatment phase was designed for 8 weeks, and the patients received the amount of drug sufficient for 10 weeks therapy, in MEMS® vials.

Measurement of compliance by MEMS
---------------------------------

Patient compliance was measured by an electronic monitoring system (MEMS, Medication Event Monitoring System, Aardex, Zug, Switzerland). The MEMS container consists of a standard tablet bottle and a cap containing a microprocessor that registers the date and time of every opening. The patients were fully familiarized with the aim and method of study and instructed how to use MEMS container correctly, that is, to open it for no other reason but to take out tablets directly before use.

Compliance with beta-blockers in angina pectoris

For the purpose of calculations, multiple MEMS openings within a short period of time (≤15 min) were filtered and not counted. All other recorded openings were considered to represent a single dose intake.

The following parameters were employed for patient compliance assessment: Overall compliance, which was defined by the number of container openings divided by the number of prescribed doses for the treatment period, and expressed as a percentage. Overall compliance was chosen to be the primary outcome measure.Days with correct number of doses taken were defined as a percentage of the treatment days with one or two doses taken for od and bd regimens, respectively.Doses taken in correct time window were defined as a percentage of the doses taken between 05:00 and 09:00 for once-daily dosage and between 06:00 and 08:00 and 18:00 and 20:00 for twice-daily dosage.Correct interdose intervals were defined as the number of correct interdose intervals divided by the number of inter-dose intervals between prescribed doses, and expressed as a percentage. Interdose interval was judged correct when the dose was taken within the period of 20--28 h after the previous dose intake in case of od regimen and within the period of 10--14 h after the previous dose in case of bd regimen.Missing doses were calculated according to the absence of registered dose intake during the periods "midnight to midnight" (24 h) in case of od regimen and "midnight to midday" or "midday to midnight" (two 12 h periods) in case of bd regimen, respectively, and expressed as percentage of prescribed doses.Therapeutic coverage was expressed as a percentage of the studied period covered with drug activity, arbitrary assuming a drug action up to 24 h after single-dose intake for od regimen and up to 12 h for bd regimen.

Drug effectiveness and tolerance; health-related quality of life
----------------------------------------------------------------

Drug effectiveness was assessed with the weekly number of chest pain episodes and weekly number of short-acting nitrates doses, both established on the basis of patients' self-report diaries. The effect of treatment on quality of life was assessed with the means of especially designed 6-item questionnaire. Moreover, general health-related quality of life was assessed with the means of EuroQol-5D (EQ-5D) generic questionnaire, which covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression ([@b28]).

Data processing and statistical analysis
----------------------------------------

Data from MEMS containers were transferred into a computer and processed using the PowerViev v. 1.3.2 program (Aardex, Zug, Switzerland). Qualitative variables were compared using a chi^2^ test. Quantitative data were expressed as means ± SD (standard deviation) and were compared using Mann-Whitney test. The statistical significance threshold was chosen at p \< 0.05.

Results
=======

Baseline characteristics
------------------------

One hundred and twelve patients entered the study and were randomized: 56 patients to each od and bd group. Thirteen patients were excluded from the analysis for different reasons (1 patient due to premature withdrawal, 6 due to premature termination due to adverse effects, and 6 patients for protocol violation). The compliance analysis was finally performed for 96 patients (47 in betaxolol and 49 in metoprolol group) due to a MEMS container lost in 2 cases and failure to download compliance data from the MEMS cap in 1 case.

The patients' demographic characteristics are given in [Table 1](#tbl1){ref-type="table"}. The two groups did not differ in terms of age, sex, and the average number of monitored days.

###### 

Demographic characteristics of studied groups

                                         Together (n = 96)   od Betaxolol (n = 47)   bd Metoprolol (n = 49)   P
  -------------------------------------- ------------------- ----------------------- ------------------------ ----
  Age (mean ± SD)                        56.8 ± 9.9          58.5 ± 9.9              55.0 ± 9.6               ns
  Male (%)                               40.6                34.0                    46.9                     ns
  Number of monitored days (mean ± SD)   66.0 ± 16.4         65.6 ± 11.8             66.3 ± 19.9              ns

ns = p \> 0.05

Overall compliance
------------------

Overall compliance assessed electronically by MEMS was better with once-daily than with twice-daily treatment: patients on betaxolol took 86.5% of recommended doses on average, while patients on metoprolol took 76.1% (p \< 0.005) ([Table 2](#tbl2){ref-type="table"}).

###### 

Parameters of patient compliance in studied groups (parameters are expressed as mean ± SD)

  Parameter                                     od Betaxolol (n = 47)   bd Metoprolol (n = 49)   p
  --------------------------------------------- ----------------------- ------------------------ ----------
  Overall compliance (%)                        86.5 ± 21.3             76.1 ± 26.3              0.002
  Days with correct number of doses taken (%)   84.4 ± 21.6             64.0 ± 31.7              \<0.0001
  Days with no dose (%)                         14.5 ± 21.4             15.2 ± 24.2              ns
  Days with extra doses (%)                     1.0 ± 1.2               1.6 ± 2.6                ns
  Missing doses (%)                             14.5 ± 21.5             24.8 ± 26.4              0.004
  Doses taken in correct time window (%)        58.6 ± 31.9             42.0 ± 28.0              0.01
  Correct interdose intervals (%)               77.4 ± 26.6             53.1 ± 32.5              \<0.0001
  Therapeutic coverage (%)                      85.6 ± 21.2             73.7 ± 25.8              0.0005
  Pill count (%)                                94.8 ± 16.2             88.8 ± 24.7              ns

ns = p \> 0.05

Assessment of daily compliance by MEMS
--------------------------------------

The difference in the percentage of days with the correct number of doses taken between the groups was highly significant in favor of the betaxolol group (84.4% vs 64.0%, p \< 0.0001). There was no significant difference in days with no dose and days with extra doses, although these two values were slightly lower in the od group.

The number of missed doses in the metoprolol group was nearly twice that of the betaxolol group (24.8% vs 14.5%, p \< 0.05).

Timing compliance
-----------------

In the betaxolol group, 58.6% of prescribed doses were taken in the correct time window compared with only 42.0% in the metoprolol group (p = 0.01) ([Table 2](#tbl2){ref-type="table"}). A statistically significant difference was also observed between the groups concerning correct interdose intervals: 77.4% of doses in the od group were taken with correct interdose intervals versus only 53.1% in the bd group (p \< 0.0001). Similarly, therapeutic coverage was significantly better in the betaxolol group (85.6% vs 73.7%, p = 0.0005).

Treatment effectiveness
-----------------------

Treatment effectiveness assessment revealed similar decrease in the number of chest pain episodes per week compared with baseline (ie, averaged number for initial 2-weeks drug-free period) in both od and bd groups (0.42/week and 0.46/week, respectively, p \> 0.05) as well as reduction in the weekly number of short-acting nitrate doses taken in case of need (0.30/week and 0.21/week, respectively, p \> 0.05) ([Figure 1](#fig1){ref-type="fig"}).

![The changes in weekly number of chest pain episodes and additional short-acting nitrates taken in case of need with time in studied groups.Two initial weeks constitute baseline period.](vhrm0302-235-f1){#fig1}

Health-related quality of life
------------------------------

The health-related quality of life parameters results are listed in [Table 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}. None of the general health-related quality of life parameters assessed by EQ-5D (ie, all 5 dimensions scores as well as mean EQ-5D utility score and EQ-5D visual analog scale \[VAS\] results) differed between od and bd groups neither at randomization nor final visit. However, a positive change was observed in both groups in case of usual activities, pain/discomfort (especially in the od group), and anxiety/depression dimensions of EQ-5D, and in the betaxolol group in case of mobility, which altogether resulted in positive change to mean EQ-5D utility scores in both od and bd groups. Similarly, EQ-5D VAS scores have improved during the follow-up. These results were consistent with those of the specific questionnaire, which showed a marked improvement in general well-being (over 70% of patients in both groups), and an important increase in physical function in the od group only.

###### 

EQ-5D dimension scores and visual analog health scale (VAS) scores at randomization (V0) and the final visit (V8)

  Dimension                  V0                                            V8                                                                                          
  -------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  **Mobility**                                                                                                                                                         
  No difficulties (%)        73.9                                          69.4                                          86.4                                          71.4
  Some difficulties (%)      26.1                                          28.6                                          13.6                                          26.5
  Extreme difficulties (%)   0                                             2.0                                           0                                             2.0
  **Self-care**                                                                                                                                                        
  No difficulties (%)        91.3                                          93.9                                          95.5                                          89.8
  Some difficulties (%)      8.7                                           6.1                                           4.5                                           10.2
  Extreme difficulties (%)   0                                             0                                             0                                             0
  **Usual activities**                                                                                                                                                 
  No difficulties (%)        76.1                                          71.4                                          81.8                                          81.6
  Some difficulties (%)      23.9                                          28.6                                          18.2                                          18.4
  Extreme difficulties (%)   0                                             0                                             0                                             0
  **Pain/discomfort**                                                                                                                                                  
  No difficulties (%)        26.1[d](#tf3-4){ref-type="table-fn"}          18.4[d](#tf3-4){ref-type="table-fn"}          72.7[d](#tf3-4){ref-type="table-fn"}          57.1[d](#tf3-4){ref-type="table-fn"}
  Some difficulties (%)      73.9[d](#tf3-4){ref-type="table-fn"}          81.6[d](#tf3-4){ref-type="table-fn"}          27.3[d](#tf3-4){ref-type="table-fn"}          42.9[d](#tf3-4){ref-type="table-fn"}
  Extreme difficulties (%)   0                                             0                                             0                                             0
  **Anxiety/depression**                                                                                                                                               
  No difficulties (%)        41.3[b](#tf3-2){ref-type="table-fn"}          38.8[c](#tf3-3){ref-type="table-fn"}          63.4[b](#tf3-2){ref-type="table-fn"}          69.4[c](#tf3-3){ref-type="table-fn"}
  Some difficulties (%)      58.7[b](#tf3-2){ref-type="table-fn"}          61.2[c](#tf3-3){ref-type="table-fn"}          36.4[b](#tf3-2){ref-type="table-fn"}          30.6[c](#tf3-3){ref-type="table-fn"}
  Extreme difficulties (%)   0                                             0                                             0                                             0
  Mean EQ-5D utility         1.38 ± 0.49[a](#tf3-1){ref-type="table-fn"}   1.42 ± 0.50[b](#tf3-2){ref-type="table-fn"}   1.20 ± 0.40[a](#tf3-1){ref-type="table-fn"}   1.27 ± 0.45[b](#tf3-2){ref-type="table-fn"}
  Mean EQ-5D VAS             63.3 ± 14.0[d](#tf3-4){ref-type="table-fn"}   63.1 ± 15.6[d](#tf3-4){ref-type="table-fn"}   75.8 ± 13.0[d](#tf3-4){ref-type="table-fn"}   75.0 ± 10.9[d](#tf3-4){ref-type="table-fn"}

p = 0.05 between V0 and V8,

p \< 0.05 between V0 and V8,

p \< 0.01 between V0 and V8,

p \< 0.001 between V0 and V8.

When filling the specific questionnaire at final visit, patients expressed a marked improvement in their general well-being (72% of patients) and modest one in terms of sleep (33% of patients), and mood (40% of patients). There was marked improvement in physical function in betaxolol group (43%) versus only slight in metoprolol group (15%). Both treatments had no influence on physical function and, notably, on sexual function ([Table 4](#tbl4){ref-type="table"}).

###### 

Changes to the quality of life dimensions after 8 weeks of active treatment

  Dimension                Final visit                            
  ------------------------ -------------------------------------- --------------------------------------
  **General well-being**                                          
  Improved (%)             73.2                                   71.7
  No change (%)            24.4                                   28.3
  Deteriorated (%)         2.4                                    0.0
  **Sleep**                                                       
  Improved                 31.0                                   34.8
  No change                66.7                                   65.2
  Deteriorated             2.4                                    0.0
  **Mood**                                                        
  Improved                 42.9                                   37.0
  No change                52.4                                   60.9
  Deteriorated             4.8                                    2.2
  **Psychical function**                                          
  Improved                 19.0                                   13.0
  No change                78.6                                   87.0
  Deteriorated             2.4                                    0.0
  **Physical function**                                           
  Improved                 42.9[b](#tf4-2){ref-type="table-fn"}   15.2[b](#tf4-2){ref-type="table-fn"}
  No change                57.1[b](#tf4-2){ref-type="table-fn"}   84.8[b](#tf4-2){ref-type="table-fn"}
  Deteriorated             0.0                                    0.0
  **Sexual function**                                             
  Improved                 0.0                                    4.3
  No change                100.0                                  95.7
  Deteriorated             0.0                                    0.0

for General well-being n = 41,

p \< 0.01 between two groups.

Tolerance and adverse effects
-----------------------------

Adverse effects occurred in 13.4% of patients (in 10.7% within od and 16.1% within bd groups). The most common adverse effect was bradycardia (3.5% in both groups). Adverse effects were the reason for patient withdrawal in 6 cases: 2 in the betaxolol group, and 4 in the metoprolol group. In most cases, adverse effects were transient and slightly expressed, no severe adverse event was observed in the trial.

Discussion
==========

Although the negative relation between non-compliance and clinical outcome seems to be obvious, the power of this relation differs greatly among the treatments ([@b19]). Indeed, even in the cardiovascular area, some drugs are more forgiving, and the condition for which they are prescribed is less life-threatening. In the case of lipid-lowering drugs, for example, there is no direct danger connected with skipping a dose, or even drug holidays (ie, discontinuation of treatment for 3 days or longer). On the other hand, there are drugs for which doctor's advice needs to be followed very carefully. Relatively small non-compliance with warfarin may result in life-threatening hemorrhagic or thrombotic complications.

Among the antianginal drugs, beta-blockers are particularly sensitive to non-compliance. Rapid cessation of their use is connected with increased risk of exacerbation of angina and acute coronary event, including heart attack, and death. Subjects who stop using beta-blocker medication have a transient four-fold increase in the relative risk of cardiovascular event ([@b27]). Those who do not adhere well to treatment regimen (ie, who took no more than 75% of prescribed medication) are 2.6 times more likely than good adherers to die within a year of follow-up ([@b18]).

Results of the present study prove that once-daily dosing of beta-blockers in stable angina pectoris leads to significantly better compliance than twice-daily as confirmed by overall compliance, days with the correct number of doses taken, and missing doses. Similar results were obtained for beta-blockers in hypertension, where those taking at least 90% of prescribed doses constituted 92.8% of the od group and 81.5% in the bd group (p = 0.009) ([@b3]). Other studies found comparable trends for other antianginal treatments ([@b5]; [@b9]; [@b21]). However, in some studies comparing once- and twice-daily dosing, better compliance for once-daily regimen was accompanied by higher percentage of no-dosing days. In a cross-over study comparing amlodipine once-daily and nifedypine SR twice-daily in the treatment of hypertension and angina pectoris, taking compliance improved in 30% of patients when switching from twice-daily to once-daily regimen but, at the same time, there was a 15% increase in the number of patients with one or more no-dosing days ([@b10]). For this reason, twice-daily regimen was regarded as superior to once-daily regimen by some authors ([@b16]). Moreover, in some studies the number of days with extra doses was higher for once-daily drugs than for twice-daily ones, which could lead to overdosing ([@b37]). Contrary to these findings, in the present study, no difference with respect to days with no doses and days with extra doses between once-daily and twice-daily groups was found.

A satisfactory timing compliance does not always follow a good dosing one. In extreme cases, only 17%--33% of drug doses were taken within an acceptable time interval (ie, 12 ± 3 h after previous dose in case of twice-daily dosing), although overall compliance was nearly perfect at 97%--99.6% ([@b32]; [@b11]). However, betaxolol, used in the present study as an od drug due to its long elimination half-life, was proven to maintain the effect on both blood pressure and heart rate longer than some other beta-blockers, even when some doses are missed ([@b20]). Moreover, the present study revealed better timing compliance (in terms of doses taken in correct time window, correct interdose intervals, and therapeutic coverage) with this drug, than with its bd comparator.

Results of studies performed in this field point at the strict association between compliance and treatment effectiveness ([@b19]). This rule was proved in a number of cardiovascular conditions and treatments ([@b8]). Among over 4000 diabetic patients in a longitudinal study, od regimen was correlated with significantly better compliance and glycemic control after 6 months' follow-up, with a significant decrease of HbA~1c~ level ([@b14]). Some recent studies, which employed electronic monitoring to assess compliance, clearly proved that once-daily regimen leads not only to better compliance, but also to better effectiveness ([@b21], [@b22]).

Nevertheless, good adherence to beta-blockers is a necessary precondition for patients to benefit from this type of treatment ([@b36]). It was observed that omission of short-acting beta-blocker resulted in significantly increased blood pressure and heart rate during the following two days ([@b20]). Betaxolol, the once-daily administered beta-blocker used in the present study, proved to be effective in the treatment of stable angina pectoris, reducing angina pectoris frequency and improving exercise capacity ([@b1]; [@b25]; [@b6]). Due to its long plasma t~1/2~ betaxolol was found to provide a long-lasting reduction in exercise-induced ischemia, longer than that found with atenolol ([@b24]). Similarly, in this study patients on betaxolol revealed more pronounced improvement in their "pain/discomfort" dimension of quality of life assessment as well as physical function, compared with the metoprolol group.

Beta-blockers were found to be effective in increasing quality of life in case of heart failure as well as hypertension ([@b13]; [@b15]; [@b29]). Due to their antianginal effect, they also enhance quality of life in case of ischemic heart disease. Betaxolol has been recently found to enhance quality of life in patients with heart failure ([@b12]). In a placebo-controlled study in hypertension, the effect of betaxolol treatment on well-being, physical state, sexual functioning, and sleep was similar to placebo, whereas cognitive acuity was slightly attenuated in this treatment group ([@b2]). Contrary to that finding, in the present study both betaxolol and metoprolol had a beneficial influence on general well-being, which was particularly marked in pain, discomfort, and mood dimensions (Tables 3 and 4). Noteworthy, this beneficial effect, at least in some aspects of quality-of-life assessment, seems to be more pronounced for od betaxolol than bd metoprolol, and one may speculate to what extent it is associated with simpler regimen, better compliance, and greater effectiveness connected with this treatment.

In assessing results of this study, it is necessary to remember its limitations. At first, due to ethical reasons, all patients were informed about the aim of the study, which could positively affect compliance. However, it is believed that this effect decreases with the time of treatment, and an 8-week active treatment study period is long enough to minimize it. Another source of limitation is using self-re-porting diaries for recording symptoms, not the objective method, which could result in potential underestimation of anginal episodes. Indeed, limited usefulness of diaries has been proved recently by comparison with electronic measurement ([@b33]). Nevertheless, neither the difference in compliance nor in effectiveness between the groups may be attributed to these factors, as both study arms were given the same conditions. Finally, beta-blockers used in this study not only differ in their pharmacokinetic properties (betaxolol, t~1/2~ 14--20 h, metoprolol, t~1/2~ 3--4 h), but they also have different pharmacodynamic properties. Therefore, in their typical dosage, 20 mg of betaxolol might induce slightly more beta-blockade than 100 mg of metoprolol tartrate ([@b4]).

Conclusions
===========

The study compared compliance in patients with stable angina pectoris, taking od versus bd beta-blockers. Using electronic measurement (MEMS), it has been found that patient compliance with od betaxolol is significantly higher than with bd metoprolol tartrate in terms of both dosing and timing. Moreover, patients on od betaxolol achieved better quality of life. Therefore, once-daily betaxolol seems to be an especially attractive beta-blocker which combines good compliance with low sensitiveness for missed doses and ensures not only high efficacy in clinical trials, but also high effectiveness in real life conditions. The results point also at general therapeutic advantage of once-daily administered beta-blockers over twice-daily administered ones in the treatment of stable angina pectoris, which is of high clinical relevance due to the life-threatening consequences of noncompliance in case of this treatment.

The author would like to express his thanks to family physicians participating in this trial: Maciej Baranski MD, Magdalena Basinska MD, Hanna Boguszewska MD, Tomasz Gula MD, Lidia Klichowicz MD, Pawel Klink MD PhD, Rafal Mazur MD, Magdalena Muras MD, Magdalena Myszkiewicz MD, Jacek Plucinski MD, Hubert Stefan MD.

The study was supported by grant from the Medical University of Lodz (No 502-16-261) and from Sanofi-Synthelabo Warsaw, Poland.
